By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
Anxiolytic tofisopam is sold in a number of European nations. It is a 2,3-benzodiazepine chemically. Tofisopam does not, however, have the same anticonvulsant, sedative, skeletal muscle relaxant, motor skill-impairing, or amnestic effects as other anxiolytic benzodiazepines.
An “anti-depressant” is a component of TOFISOPAM that is primarily used to treat depression and the anxiety that often accompanies it.
Depression is a mood condition that mostly interferes with day-to-day functioning. It results in negative emotions that lower one’s quality of life, such as grief, rage, or loss.
A mental illness known as an anxiety disorder is defined by feelings of extreme fear or worry that interfere with a person’s daily activities.
Tofisopam, a benzodiazepine predominantly used to treat depression, is a component of TOFISOPAM.It functions by enhancing the activity of a brain chemical messenger called GABA (gamma-amino-butyric acid), which inhibits the excessive and aberrant activity of brain nerve cells.
As a result, you experience less stress, a sense of wellbeing, anxiety relief, improved sleep, and a boost in energy so that you can carry out your daily tasks. Additionally, this raises quality of life.
Because TOFISOPAM has a very high potential for habit formation, only use it for the length of time and in the dosage recommended by your doctor.
Avoid stopping TOFISOPAM suddenly since it may cause nausea, aggressive behaviour, anxiety, and confusion. If you feel better, let your doctor know so that the dosage can be changed.
Do not handle any machinery or drive a car since it takes mental focus because it is known to make people drowsy.
It is a pregnancy category D medicine, so please let your doctor know if you are pregnant, trying to get pregnant, or nursing. Additionally, drinking alcohol should be avoided as it may intensify the effects of drowsiness and result in excessive sleepiness.
Global TOFISOPAM market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
Tofisopam (S-tofisopam), a drug developed by Pharmos Corporation has been successfully used in a proof-of-concept clinical trial to treat patients with hyperuricemia and gout.
The Duke Clinical Research Unit at Duke University, a specialist and key thought leader in the treatment of gout, carried out this phase 2a trial,tofisopam’s safety and effectiveness as a uric acid-lowering medication in gout patients were to be evaluated in this trial.
All patients who were investigated received tofisopam monotherapy, which was well tolerated and caused clinically significant decreases in serum urate levels.These findings encourage tofisopam’s further research and development as a treatment for hyperuricemia in gout patients.
A substance that is widely tolerated and used to treat a range of illnesses linked to stress or autonomic instability.
Tofisopam has the potential to treat an undertreated group of gout patients who don’t respond well to first-line therapy, and this group represents a sizeable global market.
Through two US-issued composition-of-matter patents, Pharmos has the legal right to both R- and S-tofisopam, the two enantiomers of racemic tofisopam.
